References
- Brandt L., Nilsson P. G., Mitelman F. Trends in incidence of acute leukemia. Lancet 1979; 1: 1069
- Bricker H. Estimate of overall treatment results in acute nonlymphocytic leukemia based on age-specific rates of incidence and of complete remission. Cancer Treat. Rep. 1985; 69: 5–11
- Groupe Francaise de Morpholologie Hematologique. French registry of acute leukemia and myelodysplastic syndrome. Cancer 1987; 60: 1385–1394
- Estey E. H., Keating M. J., McCredie K. B., Bodey G. P., Freireich E. J. Causes of initial remission failure in acute myelogenous leukemia. Blood 1982; 60: 309–315
- Swirsky D. M., De Bastos M., Parish S. E., Rees J. K. H., Hayhoe F. G. J. Features affecting outcome during remission induction of acute myeloid leukaemia in 619 adult patients. Br. J. Haematol. 1986; 64: 435–453
- Beguin Y., Bury J., Fillet G., Lennes G. Treatment of acute nonlymphocytic leukemia in young and elderly patients. Cancer 1985; 5: 2587–2592
- Heinemann V., Jehn U. Acute myeloid leukemia in the elderly: biological features and search for adequate treatment. Ann. Hematol. 1991; 63: 179–188
- Moutamat S. C., Cusack B. J., Vestal R. E. Management of drug therapy in the elderly. N. Engl. J. Med. 1989; 321: 303–309
- Balducci L., Parker M., Sexton W., Tantranond P. Pharmacology of antineoplastic agents in the elderly patients. Semin. Oncol. 1989; 16: 76–84
- Foon K. A., Zighelboim J., Yale C., Gale R. P. Intensive chemotherapy is the treatment of choice for elderly patients with acute myelogenous leukemia. Blood 1981; 58: 467–470
- Tucker J., Thomas E. A., Gregory W. M., Ganesan T. S., Malik S. T. A., Amess J. A. L., Rohatiner A. Z. S., Lister T. A. Acute myeloid leukemia in elderly adults. Hema-tol. Oncol 1990; 8: 13–21
- Walters R. S., Kantarjian H. M., Keating M. J., Estey E. M., McCredie K. B., Freireich E. J. Intensive treatment of acute leukemia in adults 70 years of age and older. Cancer 1987; 60: 149–155
- Sebban C., Archimbaud F. R., Coiffier B., Guyotat D., Treille-Ritouet D., Maupas J., Fiere D. Treatment of acute myeloid leukemia in elderly patients. Cancer 1988; 61: 227–231
- Bennet J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A. G., Gralnick H. R., Sultan C. Proposed revised criteria for the classification of acute myeloid leukaemia. Ann. Int. Med. 1985; 105: 626–669
- Rees J. K. H., Gray R., Hayhoe F. G. J. The Ninth British Medical Research Council Trial for the treatment of acute myeloid leukaemia. Haematol. Blood Trans. 1987; 30: 35–37
- Kaplan E. S., Meier P. Non parametric estimation from incomplete observation. Am. Stat. Assoc. J. 1958; 53: 657–680
- Lowemberg B., Zittoun R., Kerkhofs H., Jehn U., Abels J., Debusscher L., Cauchie Ch., Peetermans M., Solbu G., Suciu S., Stryckmans P. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J. Clin. Oncol. 1989; 7: 1268–1274
- Petti M. C., Mandelli F. Idarubicin in acute leuke-mias: experience of the Italian Cooperative Group GIMEMA. Semin. Oncol. 1989; 16(Suppl 2)10–15
- Berman E., Heller G., Santorsa J., McKenzie S., Gee T., Kempin S., Gulati S., Andreef M., Kolitz J., Gabrilove J., Reich L., Mayer K., Keefe D., Trainor K., Schluger A., Penemberg D., Raymond V., O'Reilly R., Jhanwar S., Young C., Clarkson B. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorub-icin and cytosine arabinoside in adult patients with newly diagnosed acute myeloid leukemia. Blood 1991; 77: 1666–1674